Oorsprong van het eerstegraads netwerk van Christophe Deldycke
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Turenne Capital Partenaires SA
Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.
34
| Subsidiary | Investment Managers | 34 |
France Invest
France Invest Financial ConglomeratesFinance France Invest is a French association of investors for growth that supports private equity as a lever for business creators and managers to achieve growth. The private company is based in Paris, France and was founded by Maurice Tchenio. The association is at the heart of the economy and aims to share the value created by supporting companies in their innovation and energy transition efforts.
24
| Private Company | Financial Conglomerates | 24 |
Nord Capital Partenaires SAS
12
| Joint Venture | Investment Managers | 12 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Christophe Deldycke via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
ALTRAN TECHNOLOGIES | Miscellaneous Commercial Services | Corporate Officer/Principal | |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
KIORA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Innovacom Gestion SAS
Innovacom Gestion SAS Investment ManagersFinance Innovacom Gestion SAS (Innovacom) is a venture capital firm founded in 1988 and a subsidiary of Turenne Capital Partenaires. Innovacom is headquartered in Paris, France with additional offices in Stockholm and San Francisco. | Investment Managers | Private Equity Investor Private Equity Analyst | |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Chairman Private Equity Investor | |
Sofimac Innovation SAS
Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector. | Investment Managers | Private Equity Investor Private Equity Investor | |
Ventech SA
Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Investment Managers | Private Equity Investor | |
SIGEFI Private Equity SA
SIGEFI Private Equity SA Investment ManagersFinance SIGEFI Private Equity SA is an Independent Private Equity firm founded in 1985. SPE is headquartered in Lyon. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
NOVARES GROUP | Auto Parts: OEM | Chairman Director/Board Member | |
Ardian SA
Ardian SA Investment ManagersFinance Ardian SA (Ardian) is a private equity subsidiary of Ardian Holding SAS founded in 1995. The firm is headquartered in Paris, France. | Investment Managers | Director/Board Member Private Equity Investor | |
Participex Gestion SAS
Participex Gestion SAS Investment ManagersFinance Participex Gestion SAS is a Private Equity firm, a subsidiary of Vauban Partenaires SA founded in 1974. Participex Gestion SAS is headquartered in Lille, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
INSEAD | College/University | Masters Business Admin Masters Business Admin | |
Elaia Partners SAS
Elaia Partners SAS Investment ManagersFinance Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices. | Investment Managers | Private Equity Investor | |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Miscellaneous Commercial Services | Director/Board Member | |
Université Paris Dauphine-PSL | College/University | Graduate Degree Undergraduate Degree Graduate Degree Undergraduate Degree | |
Sciences Po | College/University | Graduate Degree Undergraduate Degree | |
École Centrale Paris | College/University | Undergraduate Degree | |
ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Ecole Nationale d'Administration | College/University | Undergraduate Degree Undergraduate Degree | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
ALTUR INVESTISSEMENT | Investment Managers | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Chief Investment Officer | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
Bryan, Garnier & Co Ltd. (France) | Investment Banks/Brokers | Analyst-Equity | |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Medical Specialties | Director/Board Member | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
Renaissance Corporate SAS | Investment Managers | President President | |
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Medical Specialties | Director/Board Member | |
Genesta SAS
Genesta SAS Investment ManagersFinance Genesta SAS is an investment research firm headquartered in Paris, France. The firm was founded by Hervé Guyot in 2007 and is a subsidiary of In Extenso Finance & Transmission SAS. Genesta provides equity research to serve companies and entrepreneurs, with distribution to institutional investors and individuals. They have a team of analysts dedicated to the world of Small and Mid-Caps, positioned on the one hand in the Digital Technologies sectors (Internet Media, IT Services, Software, Video Games, etc.) and on the other in the Biotech/Medtech segments. | Investment Managers | Analyst-Equity | |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
Participations Epargne Partenaires | Director/Board Member | ||
Crédit Mutuel Equity SCR
Crédit Mutuel Equity SCR Investment ManagersFinance Credit Mutuel Equity SA is the private equity and venture capital subsidiary of Crédit Industriel et Commercial SA, which is ultimately-owned by Groupe Crédit Mutuel. The firm was founded in 1956. It is headquartered in Paris, with additional offices across France, Canada, USA, Switzerland, Germany, and United Kingdom. | Investment Managers | Director/Board Member Private Equity Investor | |
Capital Croissance SAS
Capital Croissance SAS Investment ManagersFinance Capital Croissance SAS (Capital Croissance) is a private equity firm. The firm was founded in 2010 by Eric Neuplanche. The firm headquartered in Paris, France. | Investment Managers | Founder | |
INSEEC Business School | College/University | Undergraduate Degree Director/Board Member | |
EasyRecrue SAS
EasyRecrue SAS Packaged SoftwareTechnology Services Easyrecrue SAS engages in the provision of recruitment solutions. It offers chatbot, talent nurturing, custom HR videos, video interview, live video interview, interview scheduling, AI-driven recommendations, and language tests solutions. The company was founded by Mickael Cabrol in 2013 and is headquartered in Paris, France. | Packaged Software | Director/Board Member | |
Physio-Assist SAS
Physio-Assist SAS Medical SpecialtiesHealth Technology Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France. | Medical Specialties | Director/Board Member | |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member | |
Tso Investment SARL
Tso Investment SARL Financial ConglomeratesFinance Tso Investment SARL operates as a Luxembourger associated company. The private company is based in Luxembourg, Luxembourg. | Financial Conglomerates | Corporate Officer/Principal |
Statistieken
Internationaal
Frankrijk | 37 |
Verenigde Staten | 5 |
België | 3 |
Verenigd Koninkrijk | 3 |
Spanje | 2 |
Sectoraal
Health Technology | 18 |
Finance | 17 |
Consumer Services | 9 |
Commercial Services | 5 |
Producer Manufacturing | 2 |
Operationeel
Director/Board Member | 217 |
Private Equity Investor | 78 |
Chairman | 38 |
Corporate Officer/Principal | 38 |
Private Equity Analyst | 23 |
Sterkste connecties
Insiders | |
---|---|
Antoine Papiernik | 48 |
Mounia Chaoui-Roulleau | 27 |
Cécile Mayer-Lévi | 26 |
Jean-Luc Allavena | 23 |
Guillaume Jacqueau | 19 |
François Lombard | 19 |
Fanny Letier | 18 |
Fabrice Dumonteil | 17 |
Christian Maugey | 14 |
Dominique Rencurel | 14 |
Olivier Motte | 14 |
Jean-Paul Bernardini | 13 |
Olivier Golder | 11 |
Vincent Levita | 11 |
Benoît Pastour | 10 |
- Beurs
- Insiders
- Christophe Deldycke
- Bedrijfsconnecties